155 related articles for article (PubMed ID: 22495389)
1. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice.
Casnici C; Volpe G; Crotta K; Lattuada D; Saglio G; Marelli O
J Immunother; 2012 May; 35(4):321-8. PubMed ID: 22495389
[TBL] [Abstract][Full Text] [Related]
2. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O
Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160
[TBL] [Abstract][Full Text] [Related]
3. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins.
Casnici C; Volpe G; Crotta K; Panuzzo C; Lattuada D; Cabras CA; Longhi R; Saglio G; Marelli O
Hybridoma (Larchmt); 2011 Jun; 30(3):261-9. PubMed ID: 21707361
[TBL] [Abstract][Full Text] [Related]
5. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
[TBL] [Abstract][Full Text] [Related]
7. Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients.
Casnici C; Crotta K; Volpe G; Panuzzo C; Lattuada D; Mesiano G; Saglio G; Marelli O
Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):149-156. PubMed ID: 28704165
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
Yotnda P; Firat H; Garcia-Pons F; Garcia Z; Gourru G; Vernant JP; Lemonnier FA; Leblond V; Langlade-Demoyen P
J Clin Invest; 1998 May; 101(10):2290-6. PubMed ID: 9593785
[TBL] [Abstract][Full Text] [Related]
9. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
[TBL] [Abstract][Full Text] [Related]
10. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
[TBL] [Abstract][Full Text] [Related]
11. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
Barrett J; Guimaraes A; Cullis J; Goldman JM
Stem Cells; 1993 Oct; 11 Suppl 3():104-8. PubMed ID: 8298471
[TBL] [Abstract][Full Text] [Related]
12. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes.
Greco G; Fruci D; Accapezzato D; Barnaba V; Nisini R; Alimena G; Montefusco E; Vigneti E; Butler R; Tanigaki N; Tosi R
Leukemia; 1996 Apr; 10(4):693-9. PubMed ID: 8618449
[TBL] [Abstract][Full Text] [Related]
13. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
14. Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias.
van Denderen J; ten Hacken P; Berendes P; Zegers N; Boersma W; Grosveld G; van Ewijk W
Leukemia; 1992 Nov; 6(11):1107-12. PubMed ID: 1434792
[TBL] [Abstract][Full Text] [Related]
15. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
16. Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated.
Posthuma EF; van Bergen CA; Kester MG; de Paus RA; van Veelen PA; de Ru AH; Drijfhout JW; Lurvink EG; Willemze R; Falkenburg JH
Haematologica; 2004 Sep; 89(9):1062-71. PubMed ID: 15377467
[TBL] [Abstract][Full Text] [Related]
17. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
18. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
Watanabe T; Hotta C; Koizumi S; Miyashita K; Nakabayashi J; Kurotaki D; Sato GR; Yamamoto M; Nakazawa M; Fujita H; Sakai R; Fujisawa S; Nishiyama A; Ikezawa Z; Aihara M; Ishigatsubo Y; Tamura T
Cancer Res; 2013 Nov; 73(22):6642-53. PubMed ID: 24242069
[TBL] [Abstract][Full Text] [Related]
19. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
Mundhada S; Luthra R; Cano P
BMC Cancer; 2004 Jun; 4():25. PubMed ID: 15202948
[TBL] [Abstract][Full Text] [Related]
20. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia.
Wagner WM; Ouyang Q; Pawelec G
Leukemia; 2002 Nov; 16(11):2341-3. PubMed ID: 12399986
[No Abstract] [Full Text] [Related]
[Next] [New Search]